|
About the Clinical Trials and Research Updates category
|
1
|
June 7, 2016
|
|
Propranolol
|
3
|
January 19, 2017
|
|
T cells modified with CRISPR
|
1
|
January 17, 2018
|
|
Pembrolizumab (Keytruda) and Radiotherapy
|
2
|
March 31, 2017
|
|
Tinostamustine (EDO-S101)
|
2
|
November 22, 2017
|
|
The Liddy Shriver Early Career Research Award
|
1
|
November 11, 2017
|
|
Circulating Tumor Cells in Synovial Sarcoma
|
5
|
June 28, 2015
|
|
ATR Inhibitors
|
1
|
October 18, 2017
|
|
CMB305 + Atezolizumab Phase 2 trial
|
12
|
November 13, 2015
|
|
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR
|
4
|
September 11, 2017
|
|
Sunitinib (Sutent) Plus Nivolumab (Opdivo)
|
1
|
September 15, 2017
|
|
Olaratumab with AIM
|
1
|
September 15, 2017
|
|
$500,000 Grant for Study on Synovial Sarcoma
|
1
|
August 1, 2017
|
|
PEN-866 Phase 1/2 Trial
|
1
|
July 19, 2017
|
|
SBRT and PD-1 or PD-L1 inhibitor
|
1
|
July 19, 2017
|
|
Nivolumab with or without Votrient (Pazopanib)
|
2
|
January 16, 2017
|
|
New research on Synovial Sarcoma of the head and neck! Published June 2017
|
3
|
July 16, 2017
|
|
ImmTAC from Immunocore
|
1
|
July 7, 2017
|
|
Adjuvant Chemotherapy
|
1
|
June 10, 2017
|
|
NC-6300 (Nanoparticle Epirubicin)
|
1
|
June 1, 2017
|
|
Combination of Aldoxorubicin and Ifosfamide
|
1
|
May 21, 2017
|
|
Talazoparib Plus Irinotecan
|
1
|
May 19, 2017
|
|
Factors Associated with Ifosfamide Neurotoxicity
|
1
|
May 19, 2017
|
|
Adaptimmune T-cell Therapy
|
2
|
February 10, 2016
|
|
Tazemetostat
|
8
|
August 7, 2015
|
|
Effect of Hyperbaric Oxygen Therapy on Wound healing
|
1
|
May 17, 2017
|
|
Anti-EGFR Fluorescence Agent ABY-029
|
1
|
May 17, 2017
|
|
PAZIT Clinical Trial
|
1
|
May 8, 2017
|
|
Olaratumab(Lartruvo) with Pembrolizumab (Keytruda)
|
2
|
January 12, 2017
|
|
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation
|
1
|
April 19, 2017
|
